Dexmedetomidine versus remifentanil in postoperative pain control after spinal surgery: a randomized controlled study

Wonjung Hwang, Jaemin Lee, Jihyun Park, Jin Joo, Wonjung Hwang, Jaemin Lee, Jihyun Park, Jin Joo

Abstract

Background: Total intravenous anesthesia (TIVA) is used widely in spinal surgery because inhalational anesthetics are known to decrease the amplitude of motor evoked potentials. Presently, dexmedetomidine is used as an adjuvant for propofol-based TIVA. We compared the effects of remifentanil and dexmedetomidine on pain intensity as well as the analgesic requirements after post-anesthesia care unit (PACU) discharge in patients undergoing spinal surgery.

Methods: Forty patients scheduled for posterior lumbar interbody fusion (PLIF) surgery under general anesthesia were enrolled. Anesthesia was maintained using propofol at 3-12 mg/kg/h and remifentanil at 0.01-0.2 μg/kg/min in Remifentanil group or dexmedetomidine at 0.01-0.02 μg/kg/min in Dexmedetomidine group, keeping the bispectral index between 40 and 60. Patient-controlled analgesia (PCA) made of hydromophone was applied once the patients opened their eyes in the PACU. The visual analog scale (VAS) score, PCA dosage administered, and postoperative nausea and vomiting (PONV) were recorded at the time of discharge from the PACU (T1) and at 2 (T2), 8 (T3), 24 (T4), and 48 hours (T5) after surgery.

Results: The VAS score in Remifentanil group was significantly higher than that in Dexmedetomidine group at immediate and late postoperative period (4.1 ± 2.0 vs. 2.3 ± 2.2 at T1, and 4.0 ± 2.2 vs. 2.6 ± 1.7 at T5; P < 0.05). Dexmedtomidine group had a statistically significantly lower PCA requirement at every time point after surgery except directly before discharge from the PACU (3.0 ± 1.2 ml vs. 2.3 ± 1.4 ml at T1; P > 0.05, but 69.7 ± 21.4 ml vs. 52.8 ± 10.8 ml at T5; P < 0.05). Patients in Remifentanil group displayed more PONV until 24 hours post-surgery.

Conclusions: Dexmedetomidine displayed superior efficacy in alleviating pain and in postoperative pain management for 48 hours after PLIF. Therefore, dexmedetomidine may be used instead of remifentanil as an adjuvant in propofol-based TIVA.

Trial registration: Clinical Research Information Service (CRiS) Identifier: KCT0001041.

Keywords: Dexmedetomidine; Postoperative pain; Remifentanil; Total intravenous anesthesia.

Figures

Figure 1
Figure 1
Consort flow diagram.
Figure 2
Figure 2
Comparison of postoperative VAS scores between the groups. VAS = visual analog scale; T1 = before PACU discharge; T2 = 2 hours after surgery; T3 = 8 hours after surgery; T4 = 24 hours after surgery; T5 = 48 hours after surgery. *P < 0.05.
Figure 3
Figure 3
Comparison of postoperative PCA use between the groups. PCA = patient-controlled analgesia; T1 = before PACU discharge; T2 = 2 hours after surgery; T3 = 8 hours after surgery; T4 = 24 hours after surgery; T5 = 48 hours after surgery. *P < 0.05.

References

    1. Sekimoto K, Nishikawa K, Ishizeki J, Kubo K, Saito S, Goto F. The effects of volatile anesthetics on intraoperative monitoring of myogenic motor-evoked potentials to transcranial electrical stimulation and on partial neuromuscular blockade during propofol/fentanyl/nitrous oxide anesthesia in humans. J Neurosurg Anesthesiol. 2006;18(2):106–11. doi: 10.1097/00008506-200604000-00003.
    1. Pechstein U, Nadstawek J, Zentner J, Schramm J. Isoflurane plus nitrous oxide versus propofol for recording of motor evoked potentials after high frequency repetitive electrical stimulation. Electroencephalogr Clin Neurophysiol. 1998;108(2):175–81. doi: 10.1016/S0168-5597(97)00086-5.
    1. Zheng Y, Cui S, Liu Y, Zhang J, Zhang W, Zhang J, et al. Dexmedetomidine prevents remifentanil-induced postoperative hyperalgesia and decreases spinal tyrosine phosphorylation of N-methyl-d-aspartate receptor 2B subunit. Brain Res Bull. 2012;87(4–5):427–31. doi: 10.1016/j.brainresbull.2012.01.009.
    1. Lee C, Kim YD, Kim JN. Antihyperalgesic effects of dexmedetomidine on high-dose remifentanil-induced hyperalgesia. Kor J Anesthesiol. 2013;64(4):301–7. doi: 10.4097/kjae.2013.64.4.301.
    1. De Kock M, Wiederkher P, Laghmiche A, Scholtes JL. Epidural clonidine used as the sole analgesic agent during and after abdominal surgery. A dose–response study. Anesthesiology. 1997;86(2):285–92. doi: 10.1097/00000542-199702000-00003.
    1. Venn RM, Hell J, Grounds RM. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care. 2000;4(5):302–8. doi: 10.1186/cc712.
    1. Virtanen R, Savola JM, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an alpha 2-adrenoceptor agonist. Eur J Pharmacol. 1988;150(1–2):9–14. doi: 10.1016/0014-2999(88)90744-3.
    1. McQueen-Shadfar LA, Megalla SA, White WD, Olufolabi AJ, Jones CA, Habib AS. Impact of intraoperative dexmedetomidine on postoperative analgesia following gynecologic surgery. Curr Med Res Opin. 2011;27(11):2091–7. doi: 10.1185/03007995.2011.618491.
    1. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93(2):382–94. doi: 10.1097/00000542-200008000-00016.
    1. Bulow NM, Barbosa NV, Rocha JB. Opioid consumption in total intravenous anesthesia is reduced with dexmedetomidine: a comparative study with remifentanil in gynecologic videolaparoscopic surgery. J Clin Anesth. 2007;19(4):280–5. doi: 10.1016/j.jclinane.2007.01.004.
    1. Salman N, Uzun S, Coskun F, Salman MA, Salman AE, Aypar U. Dexmedetomidine as a substitute for remifentanil in ambulatory gynecologic laparoscopic surgery. Saudi Med J. 2009;30(1):77–81.
    1. Turgut N, Turkmen A, Ali A, Altan A. Remifentanil-propofol vs dexmedetomidine-propofol–anesthesia for supratentorial craniotomy. Middle East J Anaesthesiol. 2009;20(1):63–70.
    1. Turgut N, Turkmen A, Gökkaya S, Altan A, Hatiboglu MA. Dexmedetomidine-based versus fentanyl-based total intravenous anesthesia for lumbar laminectomy. Minerva Anestesiol. 2008;74(9):469–74.
    1. Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret. Br J Anaesth. 2002;88(5):669–75. doi: 10.1093/bja/88.5.669.
    1. Park JH, Kwon JY. Remifentanil or dexmedetomidine for monitored anesthesia care during cataract surgery under topical anesthesia. Kor J Anesthesiol. 2012;63(1):92–3. doi: 10.4097/kjae.2012.63.1.92.
    1. Kissin I. Preemptive analgesia: problems with assessment of clinical significance. Methods Mol Biol. 2010;617:475–82. doi: 10.1007/978-1-60327-323-7_34.
    1. Feld JM, Hoffman WE, Stechert MM, Hoffman IW, Ananda RC. Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. J Clin Anesth. 2006;18(1):24–8. doi: 10.1016/j.jclinane.2005.05.009.
    1. Calvillo O, Ghignone M. Presynaptic effect of clonidine on unmyelinated afferent fibers in the spinal cord of the cat. Neurosci Lett. 1986;64(3):335–9. doi: 10.1016/0304-3940(86)90351-4.
    1. Carr DB, Goudas LC. Acute pain. Lancet. 1999;353(9169):2051–8. doi: 10.1016/S0140-6736(99)03313-9.
    1. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth. 1997;78(5):606–17. doi: 10.1093/bja/78.5.606.
    1. Kauppila T, Kemppainen P, Tanila H, Pertovaara A. Effect of systemic medetomidine, an alpha 2 adrenoceptor agonist, on experimental pain in humans. Anesthesiology. 1991;74(1):3–8. doi: 10.1097/00000542-199101000-00002.
    1. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–61.
    1. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104(3):570–87. doi: 10.1097/00000542-200603000-00025.
    1. Lenz H, Raeder J, Draegni T, Heyerdahl F, Schmelz M, Stubhaug A. Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans. Pain. 2011;152(6):1289–97. doi: 10.1016/j.pain.2011.02.007.
    1. Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schüttler J. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology. 2003;99(1):152–9. doi: 10.1097/00000542-200307000-00025.
    1. Angst MS, Koppert W, Pahl I, Clark DJ, Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003;106(1–2):49–57. doi: 10.1016/S0304-3959(03)00276-8.
    1. Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999;89(3):652–8.
    1. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. 1992;77(1):162–84. doi: 10.1097/00000542-199207000-00023.
    1. Kenny GN. Risk factors for postoperative nausea and vomiting. Anaesthesia. 1994;49(Suppl):6–10. doi: 10.1111/j.1365-2044.1994.tb03576.x.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner